# Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)

> **NCT03568994** · EARLY_PHASE1 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 26 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Atovaquone
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin
- **DRUG:** Etoposide
- **DRUG:** Gemtuzumab Ozogamicin

## Key facts

- **NCT ID:** NCT03568994
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-10
- **Primary completion:** 2020-09-29
- **Final completion:** 2025-09-20
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03568994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03568994, "Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03568994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*